AbbVie, Emblaveo
AbbVie Gets FDA Approval of Intravenous Antibiotic Emblaveo
AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options. The drug, which combines aztreonam and avibactam, was approved in combination with metronidazole.
The stock's fall snapped a two-day winning streak.
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...
Zacks.com on MSN2d
AbbVie Rises 8% Since Q4 Earnings: Buy, Hold or Sell the Stock?AbbVie ABBV announced strong fourth-quarter 2024 results last week, beating estimates for both earnings and sales. While earnings of $2.16 per share declined around 22% year over year, sales rose 6.1% ...
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...
The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...
Idexx Laboratories stock was rising sharply Monday, even as the S&P 500 and major indexes remained in the red. The Dow Jones ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback